Login

Frédéric Gardès' Opening Speech at the Conference: 'Innovations for Smart Mobility | Frédéric Gardès - CEO of Colas Group 00:10:00

Share On Facebook Share On Twitter

Frédéric Gardès is the CEO of Colas Group

Recent Videos

00:10:00
Dryden Gold Secures $20M+ War Chest, Delivers High-Grade Discoveries and Expands Drill Targets Across Gold Rock District|Trey Wasser,CEO & Director,Dryden Gold
00:10:00
Mitchell Services Targets $50–60M EBITDA as Rig Utilization Drives Earnings Upside| Andrew Elf,CEO,Mitchell Services Limited
00:10:00
Lomiko Metals Reports Strong Pre-Feasibility Results with $800M NPV, Advancing High-Growth Graphite Projects|Gordana Slepcev,CEO,Lomiko Metals Inc.4
00:10:00
Generative AI Meets Wet Lab: Absci Accelerates Biologic Development with Hybrid Business Model|Sean McClain,CEO,Absci
00:10:00
Obliva Aims to Transform Lives of Children with Rare Mitochondrial Disorders|Ellen K. Donnelly ,CEO,Abliva AB7
00:10:00
Abionic Repositions Bio-HDL Therapy CCR001 for Rare Kidney and Eye Disorders with Promising Early Results|Cyrille Tupin,CEO,ABIONYX Pharma
00:10:00
Abingdon Health Reports 45% H1 Revenue Growth Amid Strategic Expansion and Large Contract Wins|Dr Chris Hand,Chairman,Abingdon Health
00:10:00
EB-101 Gene Therapy Shows Promising Results in Treating Recessive Dystrophic EB|Vishwas Seshadri,CEO,Abeona Therapeutics
00:10:00
Revolutionizing Trauma Care: How AAP’s Silver Technology is Fighting Deadly Implant Infections|Rubino Di Girolamo,CEO,aap Implantate AG
00:10:00
Revolutionizing Cancer Treatment: Tumor-Agnostic mTOR Targeting Shows Breakthrough Success in Rare and Genetic-Driven Tumors| Neil Desai, Founder, Executive Chairman ,Aadi Bioscience
00:10:00
Millions Affected, No Approved Cure: 89bio Advances New Therapy for NASH|Rohan Palekar,CEO,89bio Inc2
00:10:00
Malaria Prevention Drug Arakoda Positioned to Drive Future Growth for 60 Degrees Pharmaceuticals|Geoffrey Dow,President,60 Degrees Pharmaceuticals
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4DMedical Revolutionizes Lung Imaging with CTVQ: Turning a Simple CT Scan into Functional Lung Diagnostics|Dr Andreas Fouras,CEO,4Dmedical Ltd
00:10:00
4basebio CEO Heikki Lanckriet Unveils Vision for Next-Generation Synthetic DNA and Gene Therapy Components|Heikki Lanckriet,CEO,4basebio
00:10:00
Jim Woody on Leading 180 Life Sciences: Advancing Breakthrough Biologic Therapies for Inflammation, Fibrosis, and Pain|Dr. Jim Woody,CEO,180 Life Sciences

Suggestions

00:10:00
Dealing with a start up Bio Tech company working on Pancreatic Cancer with GP 2250 and other cancer applications|Greg Bosch , CEO OF PANAVANCE THERAPEUTICS INC
00:10:00
Exploring Innovative Retirement Strategies with Rob Oliver | Rob Oliver, CEO, Oliver Financial Planning, LLC.
00:10:00
Interest Rates: A Key Driver of Market Dynamics | Andrew Clifford , CEO , Platinum Asset Management.
00:10:00
I speak with OpenText CEO Mark Barrenechea about the company's fiscal performance.
00:10:00
Birchcliff CEO: Our stock has been 'murdered', but business is strong | Chris Carlsen, CEO, Birchcliff Energy LtdBIREF:PKC
00:10:00
Market Challenges and Investment Strategies with Hilltop’s CEO Derek Kelly | Derek Kelly, CEO, Hilltop Financial Planning.
00:10:00
Transforming Culture: Geoff Yang on AI, Hip Hop, and Investment Insights | Geoff Yang, Co-Founder, Redpoint Ventures.
00:10:00
Oslo City Shopping Center, Norway's bustling hub for transportation and commerce, prioritizes fire safety and security with over 11 million annual visitors and 1,000 employees.
00:10:00
Rich Friedman: Steering Goldman Sachs' Merchant Banking Division Through Digital and Renewable Energy Transitions
00:10:00
Brisson on GFF: AIM Equity Insights | Ronald J. Kramer - Chairman of the Board and Chief Executive Officer of Griffon Corp
00:10:00
Expansion and Integration Drive Growth for Multi-Brand Franchisor Amidst Strong Interim Results | Stephen Hemsley, CEO, Franchise Brands PLC.
00:10:00
Trading of Caverion Oyj shares (trading symbol: CAV1V) commenced on the NASDAQ OMX Helsinki Main Market on July 1, 2013.

© 2017 - Neuhu+